Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines.
Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
Blockbuster Keytruda makes up nearly half of Merck’s sales. That’s becoming an issue.
Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...
Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly ...
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...
Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback